Francesco Cosentino
#134,648
Most Influential Person Now
Italian cardiologist
Francesco Cosentino's AcademicInfluence.com Rankings
Francesco Cosentinomedical Degrees
Medical
#2312
World Rank
#2729
Historical Rank
Cardiology
#210
World Rank
#215
Historical Rank
Francesco Cosentinophilosophy Degrees
Philosophy
#6729
World Rank
#9819
Historical Rank
Logic
#3850
World Rank
#5070
Historical Rank
Download Badge
Medical Philosophy
Francesco Cosentino's Degrees
- Bachelors Medicine University of Milan
Why Is Francesco Cosentino Influential?
(Suggest an Edit or Addition)Francesco Cosentino's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. (2019) (2018)
- Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I (2003) (2007)
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. (2020) (1960)
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). (2006) (1767)
- High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. (1997) (769)
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I (2013) (666)
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. (2020) (636)
- Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. (1997) (598)
- The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. (2015) (595)
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013) (468)
- High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells: Role of Protein Kinase C and Reactive Oxygen Species (2003) (456)
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018) (402)
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020) (385)
- Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. (1998) (365)
- Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways (2002) (359)
- Atherosclerosis and the two faces of endothelial nitric oxide synthase. (1998) (331)
- Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary (2007) (328)
- [Guidelines on diabetes, pre-diabetes, and cardiovascular diseases]. (2007) (321)
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2020) (310)
- Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. (1996) (297)
- Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. (1995) (294)
- Deletion of p66shc Gene Protects Against Age-Related Endothelial Dysfunction (2003) (284)
- Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation (2011) (282)
- Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. (1997) (245)
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary (2014) (245)
- Ageing, metabolism and cardiovascular disease (2016) (245)
- Gene Silencing of the Mitochondrial Adaptor p66Shc Suppresses Vascular Hyperglycemic Memory in Diabetes (2012) (212)
- Genetic deletion of p66Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress (2007) (210)
- Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. (2000) (207)
- Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. (2008) (178)
- Tetrahydrobiopterin and endothelial nitric oxide synthase activity. (1999) (175)
- Reactive Oxygen Species Mediate Endothelium-Dependent Relaxations in Tetrahydrobiopterin-Deficient Mice (2001) (175)
- Role of superoxide anions in the mediation of endothelium-dependent contractions. (1994) (173)
- Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. (2007) (157)
- Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology (2018) (155)
- Endothelial dysfunction in diabetes mellitus. (1998) (137)
- Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia (2007) (136)
- Insulin Resistance, Diabetes, and Cardiovascular Risk (2014) (136)
- Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study (2012) (131)
- Healthy lifestyle interventions to combat noncommunicable disease-a novel nonhierarchical connectivity model for key stakeholders: a policy statement from the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and Americ (2015) (129)
- Healthy lifestyle interventions to combat noncommunicable disease-a novel nonhierarchical connectivity model for key stakeholders: a policy statement from the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and Americ (2015) (129)
- Endothelium-dependent contractions to oxygen-derived free radicals in the canine basilar artery. (1993) (125)
- MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. (2016) (124)
- Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels (2017) (120)
- Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus (2015) (119)
- Non-coronary atherosclerosis. (2014) (116)
- Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II (2003) (115)
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure (2019) (114)
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) (2018) (111)
- Selective Inhibition of Protein Kinase Cβ2 Prevents Acute Effects of High Glucose on Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells (2004) (108)
- Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. (2005) (108)
- Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease (2020) (95)
- GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. (2018) (92)
- Deletion of the Activated Protein-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates Age-Related Endothelial Dysfunction (2013) (91)
- c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress (2008) (91)
- [Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. (2006) (90)
- Alterations to the nitric oxide pathway in the spontaneously hypertensive rat (1998) (87)
- Healthy Lifestyle Interventions to Combat Noncommunicable Disease—A Novel Nonhierarchical Connectivity Model for Key Stakeholders: A Policy Statement From the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and Americ (2015) (86)
- Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology (2020) (85)
- Tetrahydrobiopterin and endothelial function. (1998) (85)
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text (2007) (82)
- Oxidized Low-Density Lipoprotein Activates p66Shc via Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Protein Kinase C-&bgr;, and c-Jun N-Terminal Kinase Kinase in Human Endothelial Cells (2011) (81)
- Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial (2021) (76)
- Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. (2015) (75)
- ENDOTHELIAL FUNCTION IN CARDIOVASCULAR PRECISION MEDICINE : A POSITION PAPER ON BEHALF OF THE EUROPEAN SOCIETY OF CARDIOLOGY. (2020) (74)
- Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. (2016) (74)
- A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. (2015) (72)
- Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury. (2013) (71)
- Subarachnoid Hemorrhage and Endothelial L‐Arginine Pathway in Small Brain Stem Arteries in Dogs (1993) (71)
- Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. (2020) (71)
- Does Endothelin‐1 Play a Role in the Pathogenesis of Cerebral Vasospasm? (1994) (70)
- SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory (2013) (69)
- Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure (2020) (69)
- SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. (2013) (67)
- Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. (2013) (66)
- Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. (2013) (66)
- Endothelial Dysfunction and Stroke (2001) (63)
- Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. (2006) (62)
- Effect of endothelinA-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. (1993) (62)
- Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic β1-selective receptor blockade (2002) (59)
- Epigenetics and Immunometabolism in Diabetes and Aging (2017) (57)
- The role of p66Shc deletion in age-associated arterial dysfunction and disease states. (2008) (55)
- "In vivo" imaging of atherosclerosis. (2012) (54)
- Role of oxidative stress in endothelial insulin resistance. (2015) (54)
- Is it time to measure microalbuminuria in hypertension? (2003) (54)
- p66Shc protein, oxidative stress, and cardiovascular complications of diabetes: the missing link (2009) (53)
- Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. (2012) (51)
- Inhibition of Protein Kinase C&bgr; Prevents Foam Cell Formation by Reducing Scavenger Receptor A Expression in Human Macrophages (2008) (51)
- Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis (2020) (51)
- Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor-α (2005) (50)
- Endothelial L-arginine pathway and relaxations to vasopressin in canine basilar artery. (1993) (49)
- Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. (2000) (47)
- Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. (2018) (46)
- Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. (2016) (44)
- Alzheimer’s disease and endothelial dysfunction (2010) (42)
- Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. (2018) (42)
- Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin. (2000) (40)
- Maintenance of vascular integrity: role of nitric oxide and other bradykinin mediators. (1995) (39)
- Molecular pathways of arterial aging. (2015) (39)
- Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor (2017) (39)
- Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity (2019) (38)
- Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. (2018) (37)
- High-intensity interval training modulates retinal microvascular phenotype and DNA methylation of p66Shc gene: a randomized controlled trial (EXAMIN AGE). (2020) (36)
- Restoring the dysfunctional endothelium. (2007) (36)
- Hypertension, stroke, and endothelium (2005) (35)
- Pulsatile Stretch Induces Release of Angiotensin II and Oxidative Stress in Human Endothelial Cells: Effects of ACE Inhibition and AT1 Receptor Antagonism (2008) (33)
- Effects of blood pressure and glucose on endothelial function (2001) (33)
- Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects: A Study With Technetium-99m-Ethyl Cysteinate Dimer Single Photon Emission Computed Tomography (2009) (32)
- Diabetes and Inflammation (2004) (32)
- Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade (2011) (31)
- Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel (2021) (31)
- Anti-Aging Medicine: Molecular Basis for Endothelial Cell-Targeted Strategies – A Mini-Review (2010) (30)
- Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. (2016) (29)
- Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. (2014) (29)
- EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). (2016) (27)
- Glycogen synthase kinase-3 mediates endothelial cell activation by tumor necrosis factor-alpha. (2005) (27)
- p66(Shc)-induced redox changes drive endothelial insulin resistance. (2014) (27)
- Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. (1993) (26)
- Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors (2021) (26)
- Targeting chromatin remodeling to prevent cardiovascular disease in diabetes. (2015) (25)
- The Classification of Calcium Antagonists and their Selection in the Treatment of Hypertension (1998) (23)
- Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management (2021) (23)
- Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes (2018) (23)
- The year in cardiology 2018: prevention (2019) (22)
- Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. (2021) (21)
- Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD (2020) (21)
- Vascular Effects of Newer Cardiovascular Drugs: Focus on Nebivolol and ACE‐Inhibitors (2001) (21)
- Hyperglycemia: a bad signature on the vascular system. (2015) (20)
- The Role of Oxidative Stress in Endothelial Dysfunction and Vascular Inflammation (2010) (19)
- Nitric oxide Synthase: From Molecular Biology to Cerebrovascular Physiology (1994) (19)
- Aging and endothelial dysfunction. (2007) (18)
- Gradient of Risk and Associations with Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations from VERTIS CV. (2020) (18)
- Diabetes and Endothelial Dysfunction (2007) (17)
- Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry (2021) (17)
- p66 Shc as the engine of vascular aging. (2012) (17)
- Metabolic Syndrome (2015) (16)
- Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. (2020) (16)
- Endothelial function in coronary artery disease. (1997) (16)
- Physical activity may drive healthy microvascular ageing via downregulation of p66Shc (2020) (16)
- The year in cardiovascular medicine 2020: epidemiology and prevention. (2021) (16)
- Factor-Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis (2005) (16)
- Ertugliflozin and Slope of Chronic eGFR (2021) (15)
- Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti‐hyperglycaemic drug matters? (2020) (14)
- The year in cardiology: cardiovascular prevention. (2020) (14)
- Erratum: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (European Heart Journal (2013) 34 (3035-3087) Doi:10.1093/eurheartj/eht108) (2014) (14)
- Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials (2021) (14)
- The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel (2022) (14)
- Impaired vasorelaxant responses to natriuretic peptides in the stroke‐prone phenotype of spontaneously hypertensive rats (1998) (13)
- Endothelial Dysfunction, Hypertension and Atherosclerosis (2002) (13)
- The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up (2018) (11)
- Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials (2020) (11)
- Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk. (2019) (10)
- Diabetes and coronary artery disease: not just a risk factor (2020) (10)
- Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine. (2002) (9)
- [Metformin and left ventricular remodeling after acute myocardial infarction: molecular mechanisms and clinical implications]. (2015) (9)
- Post-COVID syndrome, inflammation, and diabetes (2022) (9)
- Nitric oxide release is impaired in hypertensive individuals with familial history of stroke. (2006) (9)
- Diabetes and ischaemic stroke: a deadly association (2018) (8)
- The role of p 66 Shc deletion in age-associated arterial dysfunction and disease states (2008) (8)
- Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health (2022) (8)
- Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial (2021) (7)
- Report from the CVOT Summit 2020: new cardiovascular and renal outcomes (2021) (7)
- Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension (2003) (7)
- Diabetes Mellitus and Metabolic Syndrome (2009) (7)
- Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. (2015) (7)
- [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD]. (2013) (6)
- The clinical relevance of dysfunctional HDL in patients with coronary artery disease: a 3-year follow-up study. (2012) (6)
- Proceedings of the Guideline Workshop 2019 - Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases and Kidney Diseases. (2020) (6)
- The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. (2020) (6)
- Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out? (2009) (6)
- Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. (2020) (6)
- Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention (2020) (6)
- The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: a neutral viewpoint. (2014) (5)
- Working Group on Peripheral Circulation (2014) (5)
- Statins Blunt Thrombin-induced Down-regulation of Endothelial Nitric Oxide Synthase Expression in Human Endothelial Cells (2006) (5)
- Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. (2022) (5)
- Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus (2022) (5)
- Glucose‐lowering treatment in cardiovascular and peripheral artery disease (2018) (5)
- Advanced glycation endproducts and plaque instability: a link beyond diabetes. (2014) (5)
- Prevalence of ‘Borderline’ Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy (2011) (4)
- Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions. (2002) (4)
- Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population. (2022) (4)
- The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact (2022) (4)
- [19] - Nitric Oxide and Endothelial Regulation of Vascular Tone (1996) (4)
- Oxidized Low-Density Lipoprotein Activates p 66 Shc via Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 , Protein Kinase C-, and c-Jun N-Terminal Kinase Kinase in Human Endothelial Cells (2011) (4)
- [Statins in cardiovascular disease. Role of Rho/Rho kinase inhibition and of Akt activation ]. (2003) (4)
- Is there any memory effect of blood pressure lowering in diabetes? (2011) (4)
- Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD) (2020) (4)
- Exercise-induced improvement of microvascular phenotype and reprogramming of p66Shc DNA methylation. (2019) (3)
- The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV (2022) (3)
- Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV (2022) (3)
- Sirtuin 1/soluble guanylyl cyclase: a nitric oxide-independent pathway to rescue ageing-induced vascular dysfunction. (2018) (3)
- Effects of Olmesartan on Endothelial Function (2007) (3)
- Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. (2017) (3)
- The year in cardiology 2017: prevention (2018) (3)
- Protocol for an Observational Blood Pressure Study (2004) (3)
- Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial (2022) (3)
- Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression (2021) (3)
- Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS) (2022) (3)
- Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. (2021) (3)
- Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies. (2019) (2)
- Use of Algae Scenedesmus as Bioindicators of Water Pollution from Active Ingredients (2017) (2)
- Mechanisms of Cardiovascular Aging (2013) (2)
- Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy. (2003) (2)
- Hyperglycemic Memory Bringing All the Strands Together (2013) (2)
- High awareness of diabetes as a key cardiovascular risk factor among healthcare professionals but suboptimal treatment: Results from a survey of the European Association of Preventive Cardiology. (2020) (2)
- Aging and longevity genes p66shc and junD mediate age-related dysfunction of angiogenic early outgrowth cells: mechanistic insights into vascular repair (2013) (2)
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds/Leeds Teaching Hospitals NHS Trust, LIGHT Laboratories, Clarendon Way (2020) (2)
- 791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV (2021) (2)
- Epidemiology, Definition, and Diagnosis of Diabetes Mellitus (2015) (2)
- Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. (2021) (2)
- Positioning newer drugs in the management of type 2 diabetes. (2021) (2)
- Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease (1998) (2)
- Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. (2021) (2)
- The lifespan determinant p66shc drives obesity-induced oxidative stress, mitochondrial dysfunction and vascular inflammation (2013) (2)
- High awareness of diabetes as a key cardiovascular risk factor among healthcare professionals but suboptimal treatment: Results from a survey of the European Association of Preventive Cardiology. (2020) (2)
- Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. (2022) (2)
- The Role of eNOS in Vascular Diseases (2007) (1)
- Therapy: Part I Diabetes and Vascular Disease : Pathophysiology, Clinical Consequences, and Medical (2012) (1)
- Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases. (2020) (1)
- Shc as the Engine of Vascular Aging (2012) (1)
- The year in cardiovascular medicine 2021: diabetes and metabolic disorders. (2022) (1)
- 783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV (2021) (1)
- One size fits all: The story of SGLT2 inhibitors in heart failure. (2022) (1)
- HN-10200 causes endothelium-independent relaxations in isolated canine arteries (1992) (1)
- Abstract 16655: Role of PKC{beta}II/p66Shc Pathway As A Determinant Of Metabolic Memory In Human Endothelial Cells (2010) (1)
- SGLT2 Inhibitors in Type 2 Diabetes Mellitus. (2022) (1)
- Abstract 12438: Vascular Hyperglycemic Memory is Abolished by in-vivo Silencing of the Mitochondrial Adaptor p66Shc (2011) (1)
- Baseline interleukin1beta expression in peripheral blood monocytes predicts the extent of weight loss and nonalcoholic fatty liver improvement in obese subjects with prediabetes or type 2 diabetes (2020) (1)
- Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs – The CAPISCO International Expert Panel (2022) (1)
- Nifedipine inhibits superoxide production induced by pulsatile stretch in human aortic endothelial cells (2000) (1)
- SGLT2i: new perspectives in diabetes and kidney disease. (2021) (1)
- Acetyltransferase gene non-derepressible 5 mediates hyperglycemia-induced endothelial oxidative stressin patients with type 2 diabetes (2013) (1)
- Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis (2022) (1)
- Prolyl-isomerase-1 (pin1) mediates hyperglycemia-induced oxidative stress, endothelial function and vascular inflammation: insights in patients with type 2 diabetes (2013) (1)
- Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence (2022) (1)
- Antioxidants and Endothelial Function: Human Studies (2006) (1)
- The year in cardiovascular medicine 2022: the top 10 papers in diabetes and metabolic disorders. (2023) (1)
- Diabetes and Cardiovascular Disease A Guide to Clinical Management: A Guide to Clinical Management (2015) (1)
- Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways (2008) (1)
- Regression of structural vascular changes after chronic treatment in hypertensives. (1991) (1)
- Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin (2022) (1)
- Mechanisms of Diabetic Atherosclerosis (2015) (1)
- Author response for "Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antihyperglycaemic drug matters?" (2019) (1)
- 865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV (2022) (1)
- Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. (2023) (1)
- A chromatin mark by SETD7 regulates myocardial inflammation in obesity-related heart failure with preserved ejection fraction (2022) (1)
- Deletion of the AP-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates Age-Related Endothelial Dysfunction (2013) (1)
- Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV (2021) (1)
- Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial (2022) (1)
- Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial (2022) (1)
- The environment, epigenetic landscape and cardiovascular risk. (2019) (0)
- Epigenetics in Cardiac Health and Disease (2016) (0)
- POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV (2021) (0)
- [Molecular mechanisms of endothelial dysfunction in diabetes]. (2002) (0)
- Diabetes and Cardiovascular Disease (2015) (0)
- Non-coronary atherosclerosis : additional costs according to involvement of vascular beds (2017) (0)
- Evolving Pathophysiological Perspectives in Endothelial Dysfunction (2004) (0)
- High Blood Pressure Cardiovascular Prevention 2011; (2011) (0)
- Vascular complications on arterial puncture site after coronaric and peripheral angiography (2011) (0)
- Adverse epigenetic remodelling of p66shc gene correlates with persistent endothelial dysfunction and oxidative stress in type 2 diabetics with optimal glycemic control (2013) (0)
- OR-28: AT2-mediated vasorelaxation by angiotensin II in SHR chronically treated with losartan (2002) (0)
- 481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV (2022) (0)
- Medical Management of Atherosclerosis in Diabetes (2003) (0)
- Abstract 5519: Enhanced Age-related Endothelial Dysfunction in Genetic Deletion of JunD (2009) (0)
- Deletion of p66Shc gene restores endothelial function in a mouse model of obesity and insulin resistance. (2011) (0)
- Highlights from International Congress (2008) (0)
- Endothelium-Dependent Contractions (2005) (0)
- Epigenetic regulation of oxidative and inflammatory phenotypes in women with gestational diabetes and offspring (2021) (0)
- Abstract 1672: Persistence of Endothelial Dysfunction as a Marker of Metabolic Memory in Diabetic Mice after Glucose Normalization (2008) (0)
- Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: The ESC-EORP CICD-LT registry. (2022) (0)
- Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease (2023) (0)
- CardioScape-II: the need to map cardiovascular funding patterns in Europe. (2020) (0)
- [Vascular medicine: the near future]. (2006) (0)
- Downregulation of JunD transcription factor leads to myocardial oxidative stress and inflammation in diabetes: role of epigenetics (2018) (0)
- Environment, Epigenetic Changes, and Cardiovascular Damage (2015) (0)
- Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. (2019) (0)
- Correction of cardiovascular risks factor after an acute coronary syndrome: impact of pharmacological therapies on a two-years follow-up (2016) (0)
- 786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV (2021) (0)
- Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. (2019) (0)
- Abstract 915: Deletion of JNK2 Prevents Hypercholesterolemia-Induced Oxidative Stress and Endothelial Dysfunction (2007) (0)
- Dysfunction of nitric oxide synthase and endothelium dependent relaxations in tetrahydrobiopterin deficient mice (1997) (0)
- Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes (2022) (0)
- Abstract 12566: Insulin Resistant Mice Lacking p66Shc Gene are Protected Against Endothelial Dysfunction (2011) (0)
- IDF2022-0796 Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV (2023) (0)
- WCN23-0356 HYPOGLYCEMIA AND KIDNEY EVENTS IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL (2023) (0)
- Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial. (2023) (0)
- Adverse epigenetic signatures driven by histone methyltransferase EZH2 contribute to hyperglycaemia-induced endothelial dysfunction (2022) (0)
- Effects of ertugliflozin on kidney outcomes in patients with heart failure at baseline in the VERTIS CV trial (2023) (0)
- HEART FAILURE OUTCOMES CAPTURED BY ADVERSE EVENT REPORTING IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL (2023) (0)
- Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis (2023) (0)
- Age-Related Endothelial Dysfunction Deletion of the AP-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates (2013) (0)
- HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL (2023) (0)
- Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor- (cid:1) (2005) (0)
- Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial (2022) (0)
- 859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV (2022) (0)
- Vascular complications of dysglycaemia (2018) (0)
- Abstract 16527: Epigenetic Signatures of p66Shc Promoter Contribute to Persistent Endothelial Dysfunction in Type 2 Diabetics With Optimal Glycemic Control (2013) (0)
- Peripheral Artery Disease (2015) (0)
- Proceedings of the Symposium "Cardiometabolic Risk and Vascular Disease--From Mechanisms to Treatment". (2012) (0)
- The role of p66 deletion in age-associated arterial dysfunction and disease states (2008) (0)
- The year in cardiology: cardiovascular prevention. The year in cardiology 2019. (2020) (0)
- 1099Optimizing patient selection in heart failure trials: the role of NT-proBNP (2018) (0)
- P4478Cardiac specific overexpression of activated protein-1 transcription factor JunD protects against oxidative stress and left ventricular dysfunction in the diabetic heart (2017) (0)
- Heterogeneity of endothelial function. (1999) (0)
- Abstract 16519: Epigenetic Remodeling of Nox2 by Acetyltransferase Gcn5 Drives Hyperglycemia-Induced Endothelial Oxidative Stress (2013) (0)
- Hyperglycemia-induced myocardial oxidative stress and inflammation persist despite optimal glycemic control: role of mitochondrial adaptor p66shc (2013) (0)
- Abstract 169: Genetic Deletion of JunD Enhances Age-Associated Endothelial Dysfunction (2006) (0)
- Highlight from International Congress (2006) (0)
- Coronary Artery Disease (2015) (0)
- Endothelial-specific deletion of methyltransferase Set7 protects mice from obesity-induced endothelial dysfunction (2022) (0)
- The combination of coronary artery disease and type 2 diabetes: a therapeutic challenge (2019) (0)
- JNK 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress (2017) (0)
- Hyperglycemia selectively increases the expression of cycloxygenase-2 in human aortic endothelial cells (2000) (0)
- 785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV (2021) (0)
- miR-673/menin/JunD axis modulates hyperglycemia-induced oxidative stress and inflammation in the diabetic heart (2020) (0)
- Abstract 16442: Reprogramming of p66Shc and JunD Improves Age-Related Dysfunction of Angiogenic Early Outgrowth Cells (2013) (0)
- 796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV (2021) (0)
- Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter] (2022) (0)
- 5210AP-1 transcription factor JunD protects against cardiac microRNA derangement in diabetes (2018) (0)
- Reprogramming Epigenetic Changes Blunts p66Shc-induced Vascular Dysfunction In Experimental and Human Obesity: Insights for Mechanisms-Based Therapeutic Strategies (2013) (0)
- Shc Protein Final Common Molecular Pathways of Aging and Cardiovascular Disease : Role of the Print (2008) (0)
- genetic deletion of P66 (sch) protects against obesity induced mithocondrial dysfunction, oxidative stress and vascular inflammation (2012) (0)
- Genetic analysis of the endothelial-dependent impaired vasorelaxation in the stroke-prone spontaneously hypertensive rat: a candidate gene approach. (1999) (0)
- Prevention and treatment of venous thromboembolism (2020) (0)
- Clinical Professorships of present and previous Collaborators of the Department of Cardiology or Cardiovascular Research at the Institute of Physiology (2010) (0)
- Cardio-diabetology: The new ‘sweetheart’ in cardiovascular prevention (2019) (0)
- Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. (2023) (0)
- The year in cardiology: cardiovascular prevention /The year in cardiology 2019 (2020) (0)
- Guideline Development for Medical Device Technology: Issues for Consideration. (2022) (0)
- Abstract 16477: Targeting Prolyl-isomerase-1 Protects Against Hyperglycemia-induced Endothelial Dysfunction and Vascular Inflammation: Alterations in Patients With Type 2 Diabetes (2013) (0)
- Oxidative Stress and Cardiovascular Disease (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Francesco Cosentino?
Francesco Cosentino is affiliated with the following schools:
